UT MD Anderson Shares Latest Research Breakthroughs
A targeted RAS inhibitor therapy daraxonrasib demonstrates the potential to improve patient outcomes over current standard treatments for patients with RAS‑mutant pancreatic cancer, according to results of a Phase 1/2 trial led by David Hong, M.D.
A series of recent research studies from the University of Texas MD Anderson Cancer Center demonstrate significant advances in targeted therapies, biomarker development, and treatment strategies across a range of cancers, including pancreatic cancer, triple‑negative breast cancer, small‑cell lung cancer, inflammatory breast cancer, appendiceal cancer, acute myeloid leukemia, and aggressive prostate cancer.
The study shows that daraxonrasib yields a 29 % response rate and 15.6 months median overall survival in a heavily pre‑treated pancreatic cancer population, indicating a possible new therapeutic option for this hard‑to‑treat disease and supporting further clinical development.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.